AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02041286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Karajishi Contour Investigational BG Monitoring System
Description: Subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi Contour Investigational BG Monitoring System with no training. All BG results are compared to reference method results obtained from subject capillary plasma. Also, study staff test subject venous blood and BG results are compared to reference method results obtained from subject venous plasma.
Study NCT03372811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TC cream
Description: A well-characterized botanical drug for topical treatment of psoriasis vulgaris
Study NCT03372811 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle
Study NCT03621488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Efficacy of Behavioral Self-Activation with virtual reality
Description: Efficacy of Behavioral Self-Activation with virtual reality
Study NCT03621488 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Efficacy of Behavioral Self-Activation without virtual reality
Description: Efficacy of Behavioral Self-Activation without virtual reality
Study NCT01943292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Study NCT00106392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: oral
Study NCT00106392 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT04024332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: ACT-541468 25 mg; administered orally
Study NCT04051385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non surgical periodontal treatment
Description: SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.
Study NCT04051385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gingival crevicular fluid and serum collection
Description: GCF with filter paper using the intracrevicular method and serum collection
Study NCT04051385 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gingival crevicular fluid and serum collection
Description: GCF with filter paper using the intracrevicular method and serum collection
Study NCT03248193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concomitant limb cryocompression and scalp cooling
Description: Part 1: Establishing optimal temperature for hypothermia therapy. Healthy subjects will undergo 3 hours of cryocompression various temperature levels.~Part 2: Establishing optimal pressure for hypothermia therapy. Each subject will undergo cryocompression (fixed at the lowest tolerated temperature established in Section 1) over 3 hours. The pressure ranges to be tested are either low, medium, or high.~Part 3: Establishing safety and tolerability of scalp hypothermia. Scalp hypothermia will be administered over 3 hours using the cooling cap attached to the cooling device.~Part 4: Establishing safety and tolerability of concomitant therapy. Subjects will undergo simultaneous scalp hypothermia and four-limb cryocompression at the temperature and pressure established in Sections 1 and 2. The concomitant therapy will be administered over 3 hours.
Study NCT03248193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concomitant limb cryocompression and scalp cooling
Description: The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Paclitaxel will be administered as a one-hour infusion. Concomitant scalp cooling and limb cryocompression sessions comprised of a pre-cooling period (one hour), continued with paclitaxel infusion and a post-cooling period (on average 30 minutes after the end of paclitaxel infusion). Overall, hypothermia will be administered for no longer than four hours.~Cryocompression will be administered on patients based on the lowest tolerated temperature and optimal pressure as determined in healthy subjects.
Study NCT02804698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education intervention
Description: 13-week educational and physical activity intervention
Study NCT02829892 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Light therapy
Description: 14-days exposure with an innovative ambient light
Study NCT04767178 — intervention group
Intervention type: DRUG
Intervention: Ibuprofen (Sanofi, Istanbul, Turkey)
Description: Each enrolled infant received oral ibuprofen at a dose of 10 mg/kg 60 min before the onset of the eye examination.
Study NCT04767178 — intervention group
Intervention type: DRUG
Intervention: Paracetamol (GlaxoSmithKline, Istanbul, Turkey)
Description: Each enrolled infant received oral paracetamol at a dose of 10 mg/kg 60 min before the onset of the eye examination.
Study NCT03660228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peri-Transfusion QOL Assessment
Description: Participants will undergo a peri-transfusion quality of life assessment (PTQA) using the Quality of Life in Myelodysplasia Scale (QUALMS)
Study NCT04182321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin & Entecavir
Description: Adding sustained-release metformin hydrochloride (1000 mg, oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
Study NCT00168688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: multi micronutrient supplement
Study NCT00168688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MN1
Description: Vitamin A 800 μg RE, Vitamin D 200 IU, Vitamin E 10 mg, Vitamin B1 1.4 mg, Vitamin B2 1.4 mg, Niacin 18 mg, Folic acid 400 μg, Vitamin B6 1.9 mg, Vitamin B12 2.6 μg, Vitamin C 70 mg, Zinc 15 mg, Iron 30 mg, Copper 2.0 mg, Selenium 65 μg, Iodine 150 μg
Study NCT00168688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MN2
Description: Vitamin A 1600 μg RE, Vitamin D 400 IU, Vitamin E 20 mg, Vitamin B1 2.8 mg, Vitamin B2 2.8 mg, Niacin 36 mg, Folic acid 800 μg, Vitamin B6 3.8 mg, Vitamin B12 5.2 μg, Vitamin C 140 mg, Zinc 30 mg, Iron 30 mg, Copper 4.0 mg, Selenium 130 μg, Iodine 300 μg
Study NCT01514812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral - modified release formulation of YM150
Study NCT01514812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral
Study NCT01514812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: oral
Study NCT02326376 — intervention group
Intervention type: DRUG
Intervention: anakinra (Kineret)
Study NCT01732250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function, for 10 days.
Study NCT01732250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin
Description: IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function, for 10 days.
Study NCT01732250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: IV meropenem, 2 gram q8h, adjusted for renal function, for up to 10 days.
Study NCT04841031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NET Treatment
Description: Narrative Exposure Therapy (NET) aims to address PTSD symptoms among survivors of mass violence and torture (Onyut et al., 2004; Schauer, et al., 2005). Mainly, different from other psychosocial interventions which require the survivor to process a single traumatic event in his or her life at a given time, NET treatment recognizes that trauma survivors undergo multiple distressing events within their lifetime (Schauer et al., 2005). Focusing on the traumatic events, the patient constructs a chronological narrative of his or her life story and a coherent narrative is then structured with the assistance of the therapist. They received NET one to three months following their screening and randomization. The therapy involves 8 to 12 individual sessions of about 90 minutes each.
Study NCT04841031 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Alternative Intervention
Description: Individuals in control group received non-NET psychosocial support in the interim that is provided to SGBV survivors as part of the Great Lakes SGBV project and will then receive NET after endline data has been collected.
Study NCT01509833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFSH
Description: Administration of rFSH for ovarian stimulation.
Study NCT01509833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: Administration of late follicular low dose hCG(100IU) for ovarian stimulation.
Study NCT01509833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: Administration of late follicular low dose hCG(200IU) for ovarian stimulation.
Study NCT02579850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5993 + Ultibro matched placebo
Description: Active medication treatment CHF 5993 and Ultibro matched placebo administered twice a day
Study NCT02579850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultibro + CHF 5993 matched placebo
Description: Active medication treatment Ultibro and CHF 5993 matched placebo administered twice a day
Study NCT02579850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central spirometry
Description: Central spirometry to assess forced expiratory volume at one second and forced vital capacity
Study NCT02579850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central spirometry
Description: Central spirometry to assess forced expiratory volume at one second and forced vital capacity
Study NCT02579850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPD assessment test
Description: COPD assessment test (CAT) at visit 1
Study NCT02579850 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COPD assessment test
Description: COPD assessment test (CAT) at visit 1
Study NCT02579850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local laboratory Assessments
Description: ECG + Standard Haematology and Biochemistry
Study NCT02579850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local laboratory Assessments
Description: ECG + Standard Haematology and Biochemistry
Study NCT02579850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saint George's Respiratory Questionnaire
Description: Saint George's Respiratory Questionnaire
Study NCT02579850 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saint George's Respiratory Questionnaire
Description: Saint George's Respiratory Questionnaire
Study NCT02579850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXACT-pro questionnaire
Description: daily from randomization (Visit 2) to end of study (Visit 7)
Study NCT02579850 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EXACT-pro questionnaire
Description: daily from randomization (Visit 2) to end of study (Visit 7)
Study NCT01431833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA
Description: Oral single dose 200 mg
Study NCT03244345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-measurement scale of sensitivity to stress/emotion
Description: Patient will answer self-questionner on Depression
Study NCT01711177 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: Placebo
Study NCT01711177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: travoprost
Description: Travatan Z is administered to newly diagnosed glaucoma patient
Study NCT01558830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranolazine
Description: ranolazine 500mg twice daily, may increase to 1000 mg twice daily for therapy optimization in treating chronic stable angina
Study NCT01339338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: warming the contrast media
Description: warm the contrast media with 37℃ water-bathing
Study NCT01558830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one pill twice daily, to increase to two pills twice daily to mirror standard ranolazine treatment strategy
Study NCT03017950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330
Study NCT03017950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D086
Study NCT03017950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 + D086
Study NCT01252017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: nilotinib (200mg/tab) 1 tab everyday
Study NCT01662258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point-of-Care diagnostic laboratory test
Description: All POC tests are FDA-cleared.
Study NCT02823288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sonke CHANGE intervention
Description: The Sonke CHANGE intervention is a multi-level model aimed at individual, group, community, and societal levels. Sonke's programming is comprised of three core components:~1. Workshops based on the premise that deeply held gender and sexuality beliefs can be critically examined and transformed in a reflective group setting. Workshops aim to challenge inequitable and harmful ideas about manhood and encourage men to take action to promote equality.~2. Community Action Teams (CATs) are comprised of interested men and women, who mobilize on a voluntary basis around issues in their neighborhoods. Methods include ambush theatre, murals painting, door to door campaigns, street soccer festivals, rallies, and community dialogues.~3. Local Advocacy is undertaken by CAT members, who aim to hold government and other duty bearers to account for VAWG prevention. CAT members join local community structures to advance community education and local government accountability.
Study NCT00608231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride Infusion
Description: Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of -1 During deep brain stimulator implantation surgery
Study NCT00608231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery
Study NCT01901237 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hatha Yoga
Description: This is a 7-week home/hospice-based instructive Hatha yoga program (available on DVD) for adolescent and young adults diagnosed with a non-curative cancer. Participants will be asked to complete a minimum of one, 75-minute yoga session per week. The DVD package includes four discs that increase in difficulty over the course of the 7-week program. The DVD focuses on postures and breathing exercises. Participants will be asked to keep track of the number and duration of yoga sessions completed over the 7-week period.
Study NCT01974245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 100,000 IU/week for 12 weeks
Study NCT01974245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 drops/ week for 12 weeks
Study NCT00779467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Study NCT00779467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study NCT00779467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Study NCT00779467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: fentanyl 2 mcg/ml
Study NCT01113281 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPM1002 live vaccine
Study NCT01113281 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: commercially available live vaccine BCG
Study NCT03247855 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: minimal invasive coronary artery bypass graft surgery
Description: coronary artery bypass grafting surgery by using a minimal invasive technique
Study NCT02442869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 1 Treatment as usual (TAU)
Description: 4-8 weeks of the treatment typically provided by that counselor with the caveat that neither DBT nor CAMS can be provided.
Study NCT02442869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 1 CAMS
Description: 4-8 weeks of Collaborative Assessment and Management of Suicidality (CAMS)
Study NCT02442869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 2 CAMS
Description: 4-16 weeks of Collaborative Assessment and Management of Suicidality (CAMS)
Study NCT02442869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 2 Dialectical Behavioral Therapy (DBT)
Description: 4-16 weeks of Dialectical Behavioral Therapy (DBT)
Study NCT02789709 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Segmental resection for colon cancer and anterior resection in patients with rectal cancer
Study NCT00004196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Study NCT00004196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymphangiography
Study NCT00004196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Observation
Study NCT02353598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumab dose level 1
Description: Participants will receive crenezumb dose level 1 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
Study NCT02353598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumab dose level 2
Description: Participants will receive crenezumb dose level 2 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
Study NCT02353598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumb dose level 3
Description: Participants will receive crenezumb dose level 3 IV infusion once every 4 weeks upto Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
Study NCT02353598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to crenezumab IV infusion once every 4 weeks upto Week 13 in double-blind treatment window.
Study NCT03157258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network Training
Description: Members of HIV+ social networks randomized to this arm will be trained to endorse compliance with medical guidelines and adherence to medical treatment regimens to their friends.
Study NCT03157258 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single Care-Related Counseling Session and Referral to Care
Description: Members of HIV+ social networks randomized to this arm will attend a single, brief care-related counseling session and referral to care at baseline.
Study NCT01988792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Human milk fortifiers
Study NCT03421392 — intervention group
Intervention type: OTHER
Intervention: non interventional study
Description: non interventional study
Study NCT04282993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable devices for identifying and measuring risk factors for ischemic stroke
Description: Identifying and monitoring cerebrovascular risk factors using wearable devices
Study NCT04282993 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care monitoring
Description: Periodical medical examinations
Study NCT00676351 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: body plethysmography
Description: Same tests were performed at 18 and 24 months. At 30 and 36 months, pulmonary function was evaluated by measuring respiratory resistances using an oscillometry system and an occlusion system
Study NCT01572454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Description: Dexmedetomidine infusion 0.2 mcg/kg/hr during anesthetic induction 0.3 - 0.7 mcg/kg/hr during the surgery
Study NCT01572454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil infusion
Description: Remifentanil infusion 0.05 - 0.3 mcg/kg/min during the anesthetic induction and surgery
Study NCT01870960 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 7 patients will be recuting to received EMDOGAIM in left side
Study NCT01870960 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 7 patients will be recuting to received EMDOGAIM in right side
Study NCT01654367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid and Aromatase Inhibitors
Description: Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy
Study NCT00456521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone SR 32 mg/ bupropion SR 360 mg/ day
Study NCT00456521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00456521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive group lifestyle modification counseling